Claudio Zamagni

5PUBLICATIONS
98CO-AUTHORS
Tumour immunologyPredictive and prognostic markersHealth informatics and information systems
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 17, 2026
Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer.

|Jan 26, 2026
Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial.

Giampaolo Bianchini, Luca Malorni, Roberta Caputo

|Sep 26, 2025
Leveraging Real-World Data From a Clinicogenomic Database Addresses the Treatment Gap in Patients With High-Grade Serous Ovarian Cancer.

Chiara Maura Ciniselli, Elena Conca, Michele Bartoletti

|Aug 12, 2025
Endometrial carcinoma and immune escape: prognostic relevance of HLA class I loss in NSMP subtype.

Marco Grillini, Jacopo Lenzi, Claudio Ceccarelli

|Sep 23, 2024
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.

Matteo Dugo, Chiun-Sheng Huang, Daniel Egle

Pageof 1

Frequent Collaborators

3 joint publications

Lucia Del Mastro

2 joint publications

Giampaolo Bianchini

2 joint publications

Grazia Arpino

2 joint publications

Stefano Tamberi